Evidence map›Paper›PMID 38951248›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2025

Cannabis-related treatment demand at the eve of German cannabis legalization - a 20-years trend analysis.

Alisa Stampf, Larissa Schwarzkopf, Albert Batalla, Daniel Feingold, Benedikt Fischer, Eva Hoch, Advisory Board of the German Addiction Care Statistical Service

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alisa Stampf *IFT Institut Für Therapieforschung, Centre for Mental Health and Addiction Research, Leopoldstrasse 175, 80804, Munich, Germany.
Larissa Schwarzkopf *IFT Institut Für Therapieforschung, Centre for Mental Health and Addiction Research, Leopoldstrasse 175, 80804, Munich, Germany. schwarzkopf@ift.de.ORCID http://orcid.org/0000-0002-9402-7700
Albert BatallaDepartment of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-5010-5121
Daniel FeingoldPsychology Department, Achva Academic College, 1 Achva, MP. Shikmim, 7980400, Arugot, Israel.ORCID http://orcid.org/0000-0002-3635-4586
Benedikt FischerResearch & Graduate Studies, University of the Fraser Valley, 33844 King Road, Abbotsford, BC, Canada.ORCID http://orcid.org/0000-0002-2186-4030
Eva HochIFT Institut Für Therapieforschung, Centre for Mental Health and Addiction Research, Leopoldstrasse 175, 80804, Munich, Germany.
Advisory Board of the German Addiction Care Statistical Service

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-2000, the prevalence of cannabis consumption has been rising internationally. This paper investigates whether cannabis-related treatment demand in German outpatient addiction care facilities (OACFs) has been following this trend. Treatment demand related to cannabis use disorder (CUD) for the period 2001 to 2021 was investigated using data from the nation-wide standardized German Addiction Care Statistical Service. Analyses covered all and first-time treatment admissions, demographics, and treatment outcomes. We identified years with significant changes in slope or direction of trends through joinpoint regression. Trends within the CUD client population were contrasted with trends among the entire OACF client population. CUD is the second-most common cause for OACF admissions in Germany. Between 2001 and 2021, the share of CUD-related cases among total OACF caseload increased from 7.1 to 19.9%, whereby the share of first-time treatment admissions declined from 79.6 to 55.6%. The share of CUD client population > 35 years almost tripled from 6.0 to 17.4%, that of female client population rose from 15.6 to 18.1%. From 2001 to 2007, the share of CUD-related treatments completed with improved symptomatology increased from 54.7 to 65.6%, followed by a marginal decline. CUD-related treatment demand is growing in Germany's OACFs, involving a client population that is increasingly older and more experienced with the addiction care system. As current intervention programmes mainly target adolescents and young adults who have been consuming cannabis only for a short time, adapting service offers to the changing client profiles appears paramount to improve treatment effectiveness.

Indexed as

Ambulatory Care FacilitiesHealth Services Needs and DemandMarijuana AbuseSubstance Abuse Treatment CentersAdolescentAdultFemaleGermanyHumansMaleMiddle AgedPattern Analysis, MachineYoung AdultAddiction counsellingAddiction treatmentCannabinoid use disorderHealth services researchOutpatient carePiecewise regression

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.